Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval entities : Incyte corporation save search
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
XNCR | $18.45 1.32% 190K
|
Health Technology
|
| O: 0.0%
H: 1.49%
C: 0.53%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.62%
H: 0.16%
C: -0.59%
minjuvi approval brazil therapeutics
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
Published: 2023-08-17 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 2.95%
H: 0.0%
C: 0.0%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.96%
H: 0.35%
C: -0.9%
sintbilo approval treatment hypercholesterolemia
Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
Published: 2023-07-03 (Crawled : 00:00) - prnewswire.com
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: 0.0%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.16%
H: 0.6%
C: -0.11%
fucaso approval treatment car-t
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
Published: 2023-04-20 (Crawled : 20:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -12.76%
H: 0.0%
C: 0.0%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.23%
H: 0.87%
C: 0.29%
opzelura approval treatment
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Published: 2023-03-27 (Crawled : 09:00) - biospace.com/
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.5%
H: 1.19%
C: 0.33%
pemazyre approval treatment
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
Published: 2023-03-22 (Crawled : 22:00) - biospace.com/
MGNX | $16.13 4.67% 150K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: -6.28%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.04%
H: 0.46%
C: -1.71%
fda approval cell treatment
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
Published: 2022-08-26 (Crawled : 15:00) - biospace.com/
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: -2.06%
pemazyre treatment fda approval
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
Published: 2022-07-19 (Crawled : 05:00) - biospace.com/
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment fda approval
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2022-06-27 (Crawled : 01:00) - prnewswire.com
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 3.36%
H: 0.35%
C: -0.71%
tyvyt treatment approval china
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma
Published: 2022-06-21 (Crawled : 01:00) - prnewswire.com
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 5.74%
H: 0.0%
C: 0.0%
tyvyt treatment approval china cell carcinoma
Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
bevagen approval food drug
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 3.73%
H: 0.09%
C: -3.98%
jakavi treatment disease approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma
Published: 2022-04-06 (Crawled : 12:00) - biospace.com/
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
Published: 2022-04-06 (Crawled : 05:00) - prnewswire.com
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment test diagnostic approval one therapy
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.21%
H: 1.43%
C: 0.41%
treatment fda fda approval dermatitis approval atopic dermatitis
Incyte Announces Health Canada Conditional Approval of Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Published: 2021-09-17 (Crawled : 22:00) - biospace.com/
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
treatment approval
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-08-26 (Crawled : 21:00) - biospace.com/
XNCR | $18.45 1.32% 190K
|
Health Technology
|
| O: 0.28%
H: 0.89%
C: -2.02%
MOR | News | $18.08 0.67% 46K
|
Health Technology
|
| O: -0.49%
H: 1.34%
C: -0.42%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.25%
H: 0.33%
C: -1.05%
treatment europe approval t-cell
Incyte Announces Health Canada Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
XNCR | $18.45 1.32% 190K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -2.7%
MOR | News | $18.08 0.67% 46K
|
Health Technology
|
| O: 4.43%
H: 0.21%
C: -0.55%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: 0.3%
H: 0.03%
C: -0.29%
canada approval treatment approval t-cell
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-27 (Crawled : 14:58) - fda.gov
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -0.05%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: -0.64%
H: 0.68%
C: 0.34%
ADCT | $4.91 4.92% 150K
|
Health Technology
|
| O: -0.05%
H: 1.0%
C: -2.76%
YMAB | $16.145 6.5% 280K
|
Health Technology
|
| O: -0.67%
H: 2.09%
C: -0.18%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.54%
H: 0.65%
C: 0.49%
REGN | News | $906.305 0.68% 87K
|
Health Technology
|
| O: -1.6%
H: 2.25%
C: 2.2%
KPTI | $1.135 0.44% 300K
|
Health Technology
|
| O: -0.47%
H: 1.53%
C: -0.35%
INCY | $51.965 0.09% 590K
|
Health Technology
|
| O: -0.41%
H: 0.14%
C: -0.84%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: 2.34%
H: 0.37%
C: -1.69%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -0.21%
H: 4.42%
C: 2.74%
BPMC | $92.38 1.95% 280K
|
Health Technology
|
| O: -0.12%
H: 0.58%
C: -0.16%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.17%
H: 2.55%
C: 0.59%
cancer approval
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.75 79.52% 1.5M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.